Literature DB >> 12864950

[Effects of arsenic trioxide on cell cycle and expression of cyclin dependent kinase inhibitors of multiple myeloma cells].

Yu-bao Chen1, Wei-jun Fu, Jian Hou, Si-qi Ding, Dong-xing Wang, Zhen-gang Yuan, Xian-tao Kong.   

Abstract

OBJECTIVE: To study the effects of arsenic trioxide (As(2)O(3)) on cell cycle and expression of cyclin dependent kinase inhibitors (CDKIs) in multiple myeloma (MM) cells, and explore its pharmacological mechanism.
METHODS: The DNA content of MM cells line HS-Sultan was analyzed by flow cytometry after exposure to As(2)O(3), the effects on expression of CDKI P15, P16 AND P21 were studied by reverse transcriptase PCR.
RESULTS: DNA flow cytometric analysis showed that As(2)O(3) induced most of HS-Sultan cells, arrest at G(0)/G(1) phase and a small fraction at G(2)/M phase and apoptosis occurred mainly in S phase. There was no expression of P15 and P16 mRNA in untreated HS-Sultan cells and 1.0 micromol/L As(2)O(3) could make them expressed after exposed 24 or 48 hours respectively. Expression of P12 mRNA was obviously elevated by As(2)O(3) comparing with that of control.
CONCLUSION: One of the pharmacological mechanisms of As(2)O(3) is to activate the expression of CDKI P15, P16 and P21, and consequently affect cell proliferation cycle.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12864950

Source DB:  PubMed          Journal:  Zhonghua Xue Ye Xue Za Zhi        ISSN: 0253-2727


  2 in total

1.  Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China.

Authors:  Xiao-mei Hu; Feng Liu; Rou Ma
Journal:  Chin J Integr Med       Date:  2010-08-10       Impact factor: 1.978

2.  Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2.

Authors:  Xiaosong Wu; Jumei Shi; Yi Wu; Yi Tao; Jun Hou; Xiuqin Meng; Xiaojing Hu; Ying Han; Wei Jiang; Siyuan Tang; Maurizio Zangari; Guido Tricot; Fenghuang Zhan
Journal:  Cancer Biol Ther       Date:  2010-12-01       Impact factor: 4.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.